Deutenzalutamide is under clinical development by Hinova Pharmaceuticals and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase III drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Deutenzalutamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HC-1119 is under development for the treatment of coronavirus disease 2019 (COVID-19), metastatic castration-resistant prostate cancer (mCRPC). It is administered through oral route. It is a small molecule acts by targeting androgen receptor. It is a first in class and best in class drug. It was also under development for the treatment of triple-negative breast cancer.
Hinova Pharmaceuticals overview
Hinova Pharmaceuticals (Hinova Pharma) operates as a drug discovery and development company. The Company focuses on the therapeutic areas where there are unmet medical needs. Hinova Pharmaceuticals serves customers globally. Hinova Pharma is headquartered in Chengdu, Sichuan, China.
For a complete picture of Deutenzalutamide’s drug-specific PTSR and LoA scores, buy the report here.